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ABSTRACT 
Colorectal cancer (CRC) is the third most common cancer in males, the second in females and is the second 
leading cause of cancer related death worldwide. Despite recent advances in chemotherapy, and targeted therapy 
for CRC, the prognosis for patients with advanced cancer has remained poor, due to drug resistance, metastasis 
and recurrence. A small fraction of cells possess tumor propagation abilities. These are termed “cancer stem 
cells (CSCs). A subset of colorectal cancer stem cells, may hold a key to controlling cancer. The cancer stem 
cell (CSC) model suggests that tumors are hierarchically organized, only CSCs possess cancer-promoting 
potential. The killing of CSCs is thought to be a critical component of effective antitumor therapies. A number 
of signaling pathways, most notably the Wingless related (Wnt), transforming growth factor-beta (TGF-β), 
Notch and Hedgehog signaling and other mechanisms have been found to be associated with CSCs in CRC. 
They play important roles in maintaining the growth and functional integrity of CSC. Many new molecules are 
now being studied to block theses pathways. Some of the molecules block the self-renewal and induction of 
apoptosis in CSCs. The design of CSC-targeted interventions is a rational target, and reduce local recurrence 
and metastasis. This review aims to summarize the issue on CSCs and signaling pathway relevant for CRC, 
which may lead to more effective therapeutic strategies for CRC.
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ABSTRAK
Kanker kolorektal (KKR) merupakan kanker urutan ketiga terbanyak pada pria, dan kedua pada wanita dan 
penyebab kematian kedua akibat kanker di dunia. Meskipun dengan kemajuan terkini pengobatan kemoterapi 
dan target terapi, prognosis pasien KKR stadium lanjut masih tetap jelek, karena resistensi obat, metastasis dan 
kambuhnya kanker. Suatu fraksi kecil sel mempunyai kemampuan untuk berkembangnya kanker yang disebut 
dengan cancer stem cells (CSCs). Subset cancer stem cells tersebut mengontrol sel kanker kolorektal. Menurut 
model CSC, tumor diatur secara hirarki dan hanya CSCs yang memiliki potensi menjadikan kanker. Mematikan 
CSCs merupakan komponen penting dalam terapi anti tumor yang efektif. Sejumlah pathway terutama Wingless 
(Wnt), transforming growth factor-beta (TGF-β), Notch dan Hedgehog signaling serta mekanisme lainnya 
telah ditemukan berhubungan dengan CSCs pada KKR. Pathways tersebut memegang peranan penting dalam 
mempertahankan pertumbuhan dan integritas fungsional dari CSCs. Banyak bahan molekul baru sedang diteliti 
untuk memblok pathway tersebut. Sebagian dari molekul memblok self-renewal dan menginduksi apoptosis 
CSCs . Rancangan target intervensi terhadap CSC adalah suatu target yang rasional, dan dapat menurunkan 
rekurensi lokal dan metastasis. Tinjauan ini mengemukakan masalah terkait CSCs dan signaling pathway terkait 
KKR, yang bisa memberi arah strategi terapi KKR yang lebih efektif. 
Kata kunci: Cancer stem cell, kanker kolorektal, signaling pathway
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INTRODUCTION
Colorectal cancer (CRC) is one of the most 
commonly diagnosed and lethal cancers worldwide.1,2 
It is the third most frequent cancer in males, and the 
second in females, and is the second leading cause of 
cancer related death worldwide. Indonesia with its 250 
million population, has age standardized incidence 
rates for colorectal cancer per 100,000 population were 
15.2 for males and 10.2 for females, and has estimated 
63,500 cases per year, and an almost similar burden to 
other countries with increasing populations.2,3,4 Most 
of CRC were located in the rectum (74.6%) than in 
colon (25.4%).5 
Colorectal carcinogenesis results from a series 
of genetic/epigenetic alterations and interactions 
with microenvironmental and germ-line factors that 
transform the normal colonic mucosa into an aberrant 
phenotype.1,6,7 There are two models of carcinogenesis: 
the stochastic and the cancer stem cell (CSC) model. 
The CSC model suggests that tumors are hierarchically 
organized and only CSCs possess cancer-promoting 
potential. Besides all the advances in target therapy, 
many patients still fail to survive because they develop 
primary and acquired resistance.8 The cause not only on 
tumor heterogeneity, but also that the tumor grows up 
in a complex ecosystem, that can influence the tumor 
main driver pathway to survival.8,9,10 Genetic diversity, 
tumor micro-environment and epigenetics are coming 
together and influence the concept of maintenance 
of stem cell state. This revolutionary idea changed 
the historical concept that tumor cells may harbour 
stem cells, and with these active properties they may 
influence carcinogenesis and patient’s outcome as 
never seen before.8
Carcinogenesis of Colorectal Cancer (CRC) 
According to the stochastic model of tumorigenesis 
suggest that any kind of cell is capable of initiating 
and promoting cancer development. The CSC model 
suggest that tumors are hierarchically organized and 
only a small fraction of cells (CSCs) possess tumor 
propagation abilities or cancer-promoting potential, 
and various molecular pathways, such as Wingless/Int 
(Wnt), Notch and Hedgehog, as well as the complex 
crosstalk network between microenvironment and 
CSCs, are involved in CRC.1,11 The CSC model 
modifies the classic Fearon and Vogelstein model, 
which is characterized by step-by-step genetic 
modifications of the adenoma to carcinoma sequence, 
by placing the normal stem cell (SC) as the primary 
candidate for being the cell of origin, by underlying the 
crucial importance of microenvironmental signals, and 
by explaining tumor heterogeneity within the context 
of a clonally evolved CSC model.1, 12
Large Intestine and Stem Cell 
The inner luminal lining of the large intestine is a 
single layer of epithelial columnar cells folded into 
finger-like invaginations, which are embedded in the 
submucosal connective tissue to form the functional 
unit of the intestine, called the crypt of Lieberkuhn. 
Normal human colon consists of millions of crypts, 
each containing about 2000 cells.12-16 The crypt base 
columnar cells (CBCCs) are regarded as stem cells 
in normal colon crypt. It is now recognized that 
colorectal cancer stem cells (CCSCs) derive from 
normal colonic crypt stem cells, located at the bottom 
area of the normal crypt, and differentiate into a 
variety of crypt cells under normal circumstances. 
Current evidence suggest that CCSCs are a special 
subgroup of cells in colorectal cancer with the ability 
to initiate differentiation towards malignant cells and 
exhibit self-renewal and metastasis potential. These 
cells differentiate into mature cells, and recruite 
cancer cells in the mature cancer tissue during CRC 
carcinogenesis.12-15 Overall, 3 main epithelial cell 
lineages comprises a crypt: the columnar cells or 
colonocytes, the mucin-secreting cells or goblet cells, 
and the endocrine cells. Turnover of these cell lineages 
is a constant process, occurring every 2-7 days under 
normal circumstances and increasing following tissue 
damage.12,17 This complex process is regulated by adult 
stem cells (ASCs) located within the crypt unit.
The Cancer Stem Cell Model in Colorectal Cancer 
(CRC)
The silencing of key genes can foster increased 
CRC-related pathway signaling (such as Wnt pathway), 
resulting in genomic instability and mutations in the 
downstream pathway genes, such as APC or β-catenin, 
and further activate these signaling pathways to foster 
colon tumorigenesis.18-19 In the CSC model, precursor 
cells are a type of partially differentiated stem cell 
which has the capacity to differentiate into one cell 
type, and therefore are also called unipotent stem cells. 
Epigenetic changes, such as aberrant methylation, may 
result in silencing of genes p16, SFRPs, GATA-4/-5 
and APC in stem/precursor cells of adult cell-renewal 
systems and may lock these cells into stem-like states 
that foster abnormal cell clonal expansion, and the 
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stem/precursor cells are transformed into preinvasive 
cancer stem cells.20 At this stage, preinvasive cancer 
stem cells turn into cancer stem cells that will 
ultimately become cancer cells. Epigenetic and genetic 
alterations play crucial roles in CRC carcinogenesis, 
while epigenetic alterations may be a predominant 
factor during early malignant transformation of colonic 
stem cells in the stem cell model. 
The current chemotherapies generally aim at 
mature cancer cells, not the CRC CSCs. Although 
these treatments can reduce the size of cancer tissue, 
they cannot completely kill CSCs. CSCs have higher 
proliferative potential and stronger resistance to 
chemotherapy and radiotherapy and differentiate 
into mature cancer cells when therapy is withdrawn, 
resulting in cancer recurrence and metastasis. 
Therefore, development of therapy targeting CSCs 
has a therapeutic potential to achieve better treatment 
to radically suppress cancer growth and metastasis.21 
CSCs are characterized by self-renewal, multipotency, 
limitless proliferation potential, angiogenic, and immune 
evasion features. These cells are considered highly 
malignant, fundamental for the growth of neoplasia, for 
recurrence, and for metastasis. Also they are considered 
resistant to chemotherapy, radiotherapy and target 
therapeutics. CSCs in the colorectal cancer, becoming 
a potential target for the treatment of the disease.8, 22-26 
CSCs have been isolated from many solid tumors in 
humans using the combination of cell surface markers, 
including CD44, CD24, ESA 18 among others. Several 
biomarkers of colorectal CSCs are as follows: CD133+/ 
CD44+/ ALDH1+, EpCAM+/ CD44+/CD24+, Lgr5+/
GPR49+, and CD133+/CD26+.8,22,27 These CSC play a 
predominant role in the initial phase of tumorigenesis. 
These facts suggest that inhibition of CSCs may be a 
therapeutic target for cancer.8 The killing of cancer stem 
cells is thought to be a critical component of effective 
antitumor therapies.
Signaling Pathways
Some pathways, including the wingless related 
(Wnt), transforming growth factor-beta (TGF-β), 
Notch and Hedgehog signaling pathways and other 
mechanisms have been found to be associated 
with CSCs in many cancer.27, 28, 29 The alterations in 
microenvironment may also be responsible for the 
tumor formation by dominance in growth promoting 
signals over the growth inhibiting signals. Therapeutic 
options follow the basic characteristic features or 
related features of the CSCs; however need to elucidate 
further for careful clinical applications.30 
The Wnt pathway plays an essential role in the 
growth and maintenance of CSCs. This pathway is 
regulated at the level of β-catenin, which is degraded 
by adenomatous polyposis coli (APC). Mutations in 
the APC gene are found in most colorectal tumors. 
As a result, β-catenin is accumulated in the nucleus, 
where it activates target genes with important 
functions in colorectal cancer development.31-33 
Wnt signaling pathway plays a pivotal role in the 
regulation of epithelial stem cell self renewal. In 
contrast, dysregulation of this signaling has been 
implicated in many epithelial cancers, including colon 
carcinogenesis.34,35,36 
TGF-β signaling pathway is one of the most 
commonly altered pathways in human cancers. This 
pathway regulates cell proliferation, differentiation, 
migration, apoptosis, stem cell maintenance and 
function TGFβ superfamily ligands bind to a type 
II serine/threonine kinase receptor, which recruits 
and phosphorylates type I receptor.31,37,38 The TGF-β 
pathway acts as a tumor suppressor pathway in healthy 
tissues but as a promoter in colorectal cancers.39 Notch 
signaling is active in colon cancer initiating cells (CC-
ICs) and is essential for the intrinsic maintenance of 
CC-ICs self-renewal and the repression of secretory 
cell lineage differentiation gene.40 Notch signaling is 
an evolutionarily conserved pathway in multicellular 
organisms, regulates cell-fate determination during 
development and in stem cells. It mediates juxtacrine 
signaling among adjacent cells. Interaction between 
Notch and its ligands initiates a signaling cascade that 
regulates differentiation, proliferation, and apoptosis.41
Hedgehog signaling, which is active in both colon 
cancer epithelial cells and, strikingly, CD133(+) cancer 
stem cells, promotes colon cancer growth, stem cell 
self renewal and metastatic behavior in advanced 
cancers.42 The hedgehog signaling is named after the 
polypeptide ligand, an intercellular signaling molecule 
called Hedgehog (Hh) found in Drosophila.43 The 
proliferation, migration, and differentiation of target 
cells are regulated by Hh signaling in a spatial, temporal, 
and concentration dependent manner. In mammals, three 
Hedgehog homologues are present, of which Sonic 
hedgehog (Shh) is the best studied.43 Several CSC target 
and agents targeting dysregulated signaling pathways in 
CSC, are as follows: (1) STAT3 (Napabucasin); (2) LRP/
FZD (Vantictmab); (3) WNT(Ipafricept); (4) Anti-DLL4 
(Demcizumab); (5) Notch (Tarex).
Many new molecules are now being developed and 
tested in clinical trials, to block these pathways. Some 
of these new small molecules block the self-renewal 
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and induction of apoptosis in CSCs. They act inhibiting 
the Wnt/β-catenin pathway, the Notch pathway and 
the hedgehog pathway. Inhibition of the STAT3 
pathway inhibits cell proliferation in vitro and reduces 
tumor growth in vivo. This pathway is critical for the 
self-regeneration and survival of CSCs in various 
neoplasms. The STAT3 pathway is connected to/β-
catenin pathway activity, which is also very important 
in the early stage of carcinogenesis and progression of 
disease in many cancers.8,28,29 
The Wnt/β-catenin pathway is mostly dysregulated 
in colorectal cancer and epidermal cancer; the 
hedgehog pathway is dysregulated in colorectal cancer, 
gastric cancer, pancreatic cancer, basal cell carcinoma 
and medulloblastoma; the Notch pathway dysregulated 
in colorectal cancer, pancreatic cancer, breast cancer 
and leukemia, and the JAK/STAT3 pathway in 
colorectal cancer, gastric cancer, breast cancer, and 
glioblastoma.8, 22, 27 
THERAPEUTIC OPTIONS 
The CSC-targeted interventions is a rational target, 
which will enhance responsiveness to traditional 
therapeutic strategies and reduce local recurrence 
and metastasis. The problem is how to identify these 
subclones which express dysregulation of these crucial 
pathways? Science has advanced and identified sub-
populations, which are eventually responsive to the 
blockage of these new molecules.1,45,46,47
It has become clearer that a tumor does not have a 
single genome, but multiple genomes, which belong 
to different sub-clones. These different sub-clones will 
contribute to intra-tumoral heterogeneity. Nevertheless, 
these different sub-clones don’t all behave in the same 
way: some are active and maintain their capacity of 
auto-renewal and are pluripotent, others remain dormant 
in a quiescent form and others are in a post-mitotic 
condition and run into apoptosis.8 The new concept 
that one or more of these clones may harbour CSC, 
redefines the driver clone “the harmful cancer clone” 
that attributes the growth and survival potential. These 
cells maintain the embryological potential to maintain 
its primary capacity to stimulate their own oncogenes 
and inhibit the tumor suppressor genes, favouring 
carcinogenesis. These clones are the hierarchy of tumor 
survival, and it should be the main aim in personalized 
medicine in the near future. The future of treatment of 
CRC lies in research on CSCs, signaling pathways. If 
these CSCs and signaling pathways better understood, 
CSC targeting via markers and targeting these aberrant 
signaling pathways are important offers a new strategy 
for cancer therapy.8,45,46,47
CONCLUSION 
Stem cells may become cancer stem cells under 
a series of epigenetic and genetic alterations. 
CSCs possess cancer promoting potential, and 
various molecular signaling pathways as well as 
the complex crosstalk network between CSCs and 
microenvironment are involved in CRC. The design 
of CSC-targeted interventions and agents targeting 
dysregulated signaling pathways in CSC, will enhance 
responsiveness to therapeutic strategies and reduce 
local recurrence and metastasis.
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